The Vanguard Group, Inc. has recently announced that it has increased stake in Matinas Biopharma Holdings Inc (AMEX:MTNB) by 0.39%. After grabbing 8.69 million shares, the institutional investor is now in possession of 33400.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.00% having worth around $1.82 million. Moreover, Geode Capital Management LLC increased its share by 1540.0 to have a control over 1.96 million shares. And Jacobs Levy Equity Management, In raised its holdings to 0.75 million shares by acquiring 0.75 million shares or 0.35% of the stake.
Matinas Biopharma Holdings Inc (MTNB) concluded trading on 12/27/23 at a closing price of $0.24, with 6.07 million shares of worth about $1.46 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.49% during that period and on Wednesday the price saw a gain of about 20.42%. Currently the company’s common shares owned by public are about 217.26M shares, out of which, 210.93M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the MTNB stock and their offered price forecasts bring an average price target of $0.65. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.00 and could fall to a lowest price of $0.30. The stock’s current price level is 63.08% above of average price target set by the analysts, while a rise to estimated low would result in gain of 20.0% for the stock. However, touching the estimated high of $1.00 would mean a gain of 76.0% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Total Market Index Fund are the top 3 mutual funds which are holding stakes in Matinas Biopharma Holdings Inc Vanguard Total Stock Market ETF is currently holding 6.02 million shares of worth totaling $1.26 million. The company recently came buying 0.0 shares which brought its stake up to 2.77% of the company’s outstanding shares. Vanguard Extended Market Index Fu bought 10020.0 shares, after which its hold over company’s outstanding shares expand to 1.09%, leaving 2.37 million shares with the mutual fund that have a worth of about $0.5 million. Fidelity Total Market Index Fund, after buying 0.39 million shares, have now control over 0.18% of the stake in the company. It holds 0.0 shares of worth $80938.0.
Matinas Biopharma Holdings Inc (AMEX: MTNB) started trading at $0.23, above $0.03 from concluding price of the previous day. Stock saw a price change of 4.88% in past 5 days and over the past one month there was a price change of 18.59%. Year-to-date (YTD), MTNB shares are showing a performance of -51.40% which decreased to -53.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.11 but also hit the highest price of $0.89 during that period. The average intraday trading volume for Matinas Biopharma Holdings Inc shares is 9.36 million. The stock is currently trading 9.23% above its 20-day simple moving average (SMA20), while that difference is up 6.43% for SMA50 and it goes to -24.52% lower than SMA200.
The Vanguard Group, Inc. acquired 8.69 million shares of Matinas Biopharma Holdings Inc having value of about $1.82 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 33400.0 shares in the company valued at close to $8016.0, or have control over 0.39% stake in the company. Matinas Biopharma Holdings Inc (AMEX: MTNB) currently have 217.26M outstanding shares and institutions hold larger chunk of about 12.09% of that. Holding of mutual funds in the company is about 4.68% while other institutional holders and individual stake holders have control over 7.41% and 11.17% of the stake respectively.
The stock has a current market capitalization of $52.79M and its 3Y-monthly beta is at 1.75. It has posted earnings per share of -$0.10 in the same period. It has Quick Ratio of 6.19 while making debt-to-equity ratio of 0.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MTNB, volatility over the week remained 10.09% while standing at 10.19% over the month.
Analysts are in expectations that Matinas Biopharma Holdings Inc (MTNB) stock would likely to be making an EPS of -$0.03 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.12 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.03 which is -$0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.02 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -9.60% while it is estimated to decrease by -9.49% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Matinas Biopharma Holdings Inc (MTNB)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
